Beck-Jensen J E, Kollerup G, Sørensen H A, Pors Nielsen S, Sørensen O H
Osteoporosis Research Centre, Copenhagen Municipal Hospital, Denmark.
Scand J Clin Lab Invest. 1997 Jul;57(4):351-9. doi: 10.3109/00365519709099408.
Biochemical markers of bone turnover are used to estimate the rate of bone loss in the individual osteoporotic patient. During recent years it has become increasingly clear that the biological variability of biochemical bone markers has to be taken into consideration in the evaluation of their usefulness in the clinical setting. Eleven premenopausal, 8 perimenopausal and 11 postmenopausal healthy women were included. We assessed the analytical and the biological components of variation for a number of resorptive and formative bone markers: u-hydroxyproline, u-pyridinoline, and u-deoxypyridinoline together with u-calcium and u-creatinine, s-total alkaline phosphatases and s-osteocalcin. Blood and urine samples were collected five times with 7-day intervals. Urinary parameters were expressed as outputs and corrected for creatinine in fasting night urines and second void fasting morning urines. The absolute values differed with a tendency towards increasing values in the postmenopausal women, but the biological variations in relation to menopausal status were not different. The biological variability was much higher for the urinary resorptive markers than for the formative markers in the blood. The critical difference expressing the difference needed between two serial results from the same person to be significant at a 5% level was 15% for s-alkaline phosphatases, 18% for s-osteocalcin, and lowest in the second void fasting morning urines with values of 28% and 34% for u-pyridinoline/creatinine and u-deoxypyridinoline/creatinine, and 50% and 112% for u-hydroxyproline/creatinine and u-calcium/creatinine, respectively. The index of individuality, denoting the individual variation divided by the variation between subjects, was in the range from 0.19 for s-alkaline phosphatases to 1.23 for u-hydroxyproline/minute in second void fasting morning urine making the use of conventional reference intervals difficult. Low indices, however, indicate high test performance and offer the possibility of stratification of persons within a range. The number of samples required to determine the true individual mean value +/- 5% for the single person, ranged from 5 for s-total alkaline phosphatases, 6 for s-osteocalcin, 23 for u-deoxypyridinoline/creatinine in the fasting morning urine to over two hundred for u-calcium analytes. It is concluded that, due to high biological variation, a single measurement of biochemical markers of bone turnover is of limited utility in the individual person. We recommend that routine clinical use of biochemical markers should be restricted until further evidence justifies it.
骨转换生化标志物用于评估个体骨质疏松患者的骨质流失率。近年来,越来越清楚的是,在评估其在临床环境中的有用性时,必须考虑骨生化标志物的生物学变异性。研究纳入了11名绝经前、8名围绝经期和11名绝经后健康女性。我们评估了多种骨吸收和骨形成标志物的分析变异和生物学变异:尿羟脯氨酸、尿吡啶啉、尿脱氧吡啶啉以及尿钙和尿肌酐、血清总碱性磷酸酶和血清骨钙素。每隔7天采集5次血液和尿液样本。尿参数以排出量表示,并根据空腹夜间尿液和第二次晨尿中的肌酐进行校正。绝经后女性的绝对值有所不同,且有升高的趋势,但与绝经状态相关的生物学变异并无差异。尿骨吸收标志物的生物学变异性远高于血液中的骨形成标志物。在5%水平上,同一个人两次连续结果之间具有显著差异所需的临界差异,血清碱性磷酸酶为15%,血清骨钙素为18%,在第二次晨尿中最低,尿吡啶啉/肌酐和尿脱氧吡啶啉/肌酐分别为28%和34%,尿羟脯氨酸/肌酐和尿钙/肌酐分别为50%和112%。个体指数表示个体变异除以个体间变异,在第二次晨尿中,血清碱性磷酸酶为0.19,尿羟脯氨酸/分钟为1.23,这使得使用传统参考区间变得困难。然而,低指数表明检测性能高,并提供了在一定范围内对个体进行分层的可能性。确定单人真实个体均值±5%所需的样本数量,血清总碱性磷酸酶为5个,血清骨钙素为6个,空腹晨尿中尿脱氧吡啶啉/肌酐为23个,尿钙分析物则超过200个。结论是,由于生物学变异较大,单次测量骨转换生化标志物在个体中的效用有限。我们建议在有进一步证据证明其合理性之前,应限制骨生化标志物在常规临床中的使用。